Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

CBT Plus SMC Compared to SMC for Persistent Physical Symptoms in Secondary Care (PRINCE) (PRINCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02426788
Recruitment Status : Completed
First Posted : April 27, 2015
Last Update Posted : May 9, 2019
Sponsor:
Collaborator:
South London and Maudsley NHS Foundation Trust
Information provided by (Responsible Party):
King's College London

Brief Summary:
Brief Summary: Persistent Physical Symptoms (PPS), also known as medically unexplained symptoms (MUS) is a term used to describe a range of persistent bodily symptoms for which the exact cause is unclear. Between 20 and 40% of patients in primary care, and about 50% in secondary care experience PPS. Not only are PPS common, but the overlap across different patient groups may indicate that these phenomena are transdiagnostic. PPS are associated with profound disability and high health care costs, and if left untreated the prognosis of these patients is poor. There is an accumulating body of evidence demonstrating that cognitive behavioural interventions can reduce levels of symptoms and improve functioning in patients with PPS. A pragmatic randomised controlled trial (RCT) was designed to evaluate the clinical and cost-effectiveness of cognitive behavioural therapy (CBT) + Standard Medical Care (SMC) versus Standard Medical Care alone, in the treatment of patients with PPS. The trial will focus on patients with a variety of symptoms (e.g., non-cardiac chest pain, fibromyalgia), across secondary care clinics (e.g., neurology, cardiology, and rheumatology).

Condition or disease Intervention/treatment Phase
Persistent Physical Symptoms (PPS) Behavioral: Cognitive behavioural therapy (CBT) Not Applicable

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 324 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The PRINCE Secondary Study: Persistent Physical Symptoms Reduction Intervention: a System Change and Evaluation in Secondary Care
Study Start Date : July 2015
Actual Primary Completion Date : January 2019
Actual Study Completion Date : January 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Health Checkup

Arm Intervention/treatment
Experimental: CBT+SMC

Cognitive behavioural therapy + Standard Medical Care (cognitive-behavioural therapy+SMC):

8 hour-long manual-based CBT sessions with a therapist, weekly or fortnightly.

Behavioral: Cognitive behavioural therapy (CBT)
Behavioral: Cognitive behavioural therapy (CBT) The CBT intervention used in the trial has been adapted for people with PPS and it is based on a model of understanding PPS (Deary et al 2007). The therapy aims to help the patient develop an understanding of the relationship between cognitive, physiological and behavioural aspects of their problem; to understand factors that may be maintaining the problem and to learn how to modify their behavioural and cognitive responses in order to improve quality of life. The approach is transdiagnostic in that it targets processes and underlying mechanisms that affect disorders similarly, rather than focusing on how they are diagnostically different. The approach is personalised during therapy following a detailed assessment.

No Intervention: Standard Medical Care (SMC)
Participants assigned to the SMC group (i.e., control group) will receive all the treatment and support they would otherwise receive outside of a research trial.



Primary Outcome Measures :
  1. Work and social adjustment scale [ Time Frame: 52 weeks post randomisation ]
    Measures impairment in functioning


Secondary Outcome Measures :
  1. Persistent Physical Symptom Questionnaire [ Time Frame: 52 weeks post randomisation ]
    Measures severity, distress, interference and problematic nature of PPS

  2. Patient Health Questionnaire-15 (PHQ-15) [ Time Frame: 52 weeks post randomisation ]
    Measures physical symptoms severity

  3. Patient Health Questionnaire-9 (PHQ-9) [ Time Frame: 52 weeks post randomisation ]
    Measures mood

  4. Generalized Anxiety Disorder-7 (GAD-7) [ Time Frame: 52 weeks post randomisation ]
    Measures generalised anxiety

  5. Clinical Global Impression (CGI) [ Time Frame: 52 weeks post randomisation ]
    Measures patient's perception of their general health improvement

  6. Client Service Receipt Inventory (CSRI) [ Time Frame: 52 weeks post randomisation ]
    Measures health care service receipt, direct and indirect costs of illness, and cost-effectiveness of interventions

  7. EuroQol-5D (EQ-5D) [ Time Frame: 52 weeks post randomisation ]
    Measures health outcome

  8. Cognitive Behavioural Responses Questionnaire [ Time Frame: 52 weeks post randomisation ]
    Measures beliefs and behaviours

  9. Acceptance scale [ Time Frame: 52 weeks post randomisation ]
    assesses degree of acceptance of difficult symptoms


Other Outcome Measures:
  1. PSYCHLOPS [ Time Frame: 52 weeks post randomisation ]
    Measures improvement of patient-defined self-rated problems



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • Adults (18 - 70 yrs)
  • Patients with PPS from broad patient populations (e.g., fibromyalgia, non-cardiac chest pain, postural orthostatic tachycardia syndrome, neurological symptoms);
  • Significant functional impairment/moderately severe disability - as indicated by the Work and Social Adjustment Scale (WSAS) score (i.e., a minimum score of 10);
  • Ability to complete diaries and questionnaires in English;
  • Willingness to complete all trial visits;
  • Ability to give written informed consent.

Exclusion Criteria:

  • Active psychosis;
  • Factitious disorder;
  • Headaches as the only PPS;
  • Non-epileptic seizures
  • Current alcohol dependence or drug addiction as assessed by the clinician;
  • Current benzodiazepine use exceeding the equivalent of 10mg diazepam/day;
  • The patient is currently receiving CBT/CBT based approach psychotherapy, or has received CBT/CBT based approach psychotherapy in the past year, for their PPS;
  • The patient is thought to be at imminent risk of self-harm;
  • Patient is taking part in PRINCE Primary trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02426788


Locations
Layout table for location information
United Kingdom
Guy's Hospital
London, United Kingdom
King's College Hospital
London, United Kingdom
Queen Elizabeth Hospital
London, United Kingdom
Royal Free Hospital
London, United Kingdom
St Thomas' Hospital
London, United Kingdom
University Hospital Lewisham
London, United Kingdom
Princess Royal University Hospital
Orpington, United Kingdom
Sponsors and Collaborators
King's College London
South London and Maudsley NHS Foundation Trust
Investigators
Layout table for investigator information
Principal Investigator: Trudie Chalder, PhD King's College London

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: King's College London
ClinicalTrials.gov Identifier: NCT02426788     History of Changes
Other Study ID Numbers: STR130202 (Secondary)
First Posted: April 27, 2015    Key Record Dates
Last Update Posted: May 9, 2019
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by King's College London:
medically unexplained
fibromyalgia
postural orthostatic tachycardia syndrome (PoTs)
non-cardiac chest pain
CFS
irritable bowel syndrome (IBS)
functional neurological
chronic pain
hyperventilation
unexplained cough
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplastic Processes
Neoplasms
Pathologic Processes